Psychopharmakotherapie griffbereit Medikamente, psychoaktive Genussmittel und Drogen

Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: Dreher, Jan 1971- (VerfasserIn)
Format: Buch
Sprache:German
Veröffentlicht: Stuttgart Schattauer [2016]
Ausgabe:2., vollständig aktualisierte und erweiterte Auflage
Schriftenreihe:griffbereit
Schlagworte:
Online-Zugang:Inhaltsverzeichnis
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

MARC

LEADER 00000nam a2200000 c 4500
001 BV043376770
003 DE-604
005 20160915
007 t|
008 160218s2016 xx a||| |||| 00||| ger d
015 |a 15,N51  |2 dnb 
016 7 |a 1079863125  |2 DE-101 
020 |a 3794531833  |9 3-7945-3183-3 
020 |a 9783794531837  |c : ca. EUR 25.70 (AT), ca. EUR 24.99 (DE)  |9 978-3-7945-3183-7 
024 3 |a 9783794531837 
035 |a (OCoLC)956474717 
035 |a (DE-599)DNB1079863125 
040 |a DE-604  |b ger  |e rda 
041 0 |a ger 
049 |a DE-355  |a DE-1052  |a DE-70  |a DE-11  |a DE-M483  |a DE-824  |a DE-1949  |a DE-19  |a DE-128 
082 0 |a 610  |2 23 
084 |a CZ 2000  |0 (DE-625)19239:  |2 rvk 
084 |a XI 5803  |0 (DE-625)153018:12909  |2 rvk 
084 |a 610  |2 sdnb 
084 |a QV 77  |2 nlm 
100 1 |a Dreher, Jan  |d 1971-  |e Verfasser  |0 (DE-588)120465655  |4 aut 
245 1 0 |a Psychopharmakotherapie griffbereit  |b Medikamente, psychoaktive Genussmittel und Drogen  |c Jan Dreher 
250 |a 2., vollständig aktualisierte und erweiterte Auflage 
264 1 |a Stuttgart  |b Schattauer  |c [2016] 
264 4 |c © 2016 
300 |a XIV, 267 Seiten  |b 10 Illustrationen, Diagramme  |c 18.5 cm x 12 cm 
336 |b txt  |2 rdacontent 
337 |b n  |2 rdamedia 
338 |b nc  |2 rdacarrier 
490 0 |a griffbereit 
650 2 |a Mental Disorders - drug therapy 
650 2 |a Psychotropic Drugs - therapeutic use 
650 0 7 |a Psychopharmakotherapie  |0 (DE-588)4236424-3  |2 gnd  |9 rswk-swf 
653 |a Ärzte in Weiterbildung zum Facharzt für Psychiatrie und Psychotherapie; Haus- und Allgemeinärzte; andere Ärzte, die immer wieder mal mit Psychopharmakologie zu tun haben; Medizinstudenten; Psychologen in Ausbildung (speziell Psychologen in Weiterbildung zum Psychologischen Psychotherapeuten); Pflegekräfte auf psychiatrischen Stationen; Sozialarbeiter, die in einer psychiatrischen Klinik tätig sind; Betroffene und Angehörige 
653 |a ADHS-Therapeutika 
653 |a Acetylcholinesterasehemmer 
653 |a extrapyramidalmotorische Störungen 
689 0 0 |a Psychopharmakotherapie  |0 (DE-588)4236424-3  |D s 
689 0 |5 DE-604 
710 2 |a Schattauer GmbH  |0 (DE-588)1065173687  |4 pbl 
776 0 8 |i Erscheint auch als  |n Online-Ausgabe, EPUB  |z 978-3-7945-9041-4 
776 0 8 |i Erscheint auch als  |n Online-Ausgabe, PDF  |z 978-3-7945-9011-7 
856 4 2 |m DNB Datenaustausch  |q application/pdf  |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=028795572&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA  |3 Inhaltsverzeichnis 
943 1 |a oai:aleph.bib-bvb.de:BVB01-028795572 

Datensatz im Suchindex

DE-19_call_number 0760/8 Med.G 9667
DE-19_location 55
DE-BY-UBM_katkey 5335121
DE-BY-UBM_media_number 99995551486
DE-BY-UBR_call_number 00/CZ 2000 D771(2)
86/VS 7150 D771(2)
DE-BY-UBR_katkey 5724783
DE-BY-UBR_location 00
86
DE-BY-UBR_media_number 069039677189
069041598166
_version_ 1823056011599020032
adam_text INHALT A N L E I T U N G ........................................................................................................... 1 1 PSYCHOPHARMAKA *M UE BERBLICK....................................... 5 1.1 WAHL DES P SYCHOPHARM AKONS......................................................... 6 1.2 W IRKUNG DER N E U RO TRA N S M ITTE R....................................................... 8 1.3 VERORDNUNGSHAEUFIGKEIT DER PSYCHOPHARMAKA . . . . . . . . . . . . ** 2 ANTIDEPRESSIVA .................................................................. 13 2.1 E IN TE ILU N G ................................................................................................ 13 2.2 G E S C H IC H TE ............................................................................................. 14 2.3 W IRK P RIN Z IP IE N ....................................................................................... 14 2.4 T H E RA P IE .................................................................................................. 16 2.4.1 DEPRESSION................................................................................................ 16 2.4.2 ANGSTSTOERUNGEN....................................................................................... 20 SNRI, SSRI.................................................................................................. 20 P REGABALIN................................................................................................ 21 BENZODIAZEPINE....................................................................................... 21 2.4.3 ZWANGSERKRANKUNGEN ............................................................................. 23 2.4.4 SOMATOFORME STORUNGEN....................................................................... 26 PSYCHOTHERAPIE......................................................................................... 26 SNRI, SSRI ODER TRIZYKLIKA .................................................................. 26 SCHMERZBEHANDLUNG................................................................................ 27 BENZODIAZEPINE....................................................................................... 28 2.5 W IRKS TO FFKLA S S E N ................................................................................. 28 2.5.1 SSRI ........................................................................................................... 28 2.5.2 S N R L........................................................................................................... 29 2.5.3 N A R I........................................................................................................... 29 2.5.4 TRI UND TETRAZYKLISCHE ANTID^^ ................................................ 30 2.5.5 ***-H E M M ER......................................................................................... 30 2.6 W IR K S T O F F E ............................................................................................. 32 2.6.1 CITALOPRAM ................................................................................................ 32 2.6.2 ESCITALOPRAM ............................................................................................. 36 2.6.3 VENLAFAXIN ................................................................................................ 39 2.6.4 D ULOXETIN.................................................................................................. 41 2.6.5 VORFIOXETIN................................................................................................ 43 2.6.6 M IRTAZAP JN ................................................................................................ 46 2.6.7 AGOMELATIN................................................................................................ 48 2 .6 3 AMITRIPTYLIN ............................................................................................ 51 2.6.9 M O C L O B E M I D . . . . . . . . . . . . . . . . 53 2.7 N EB EN W IRKU N G EN .................................................................................. 55 2.7.1 SEROTONINSYNDROM.................................................................................. 55 2.7.2 ANTIDEPRESSIVA UND SUIZIDALITAET ........................................................... 57 2.7.3 ABSETZERSCHEINUNGEN ............................................................................. 58 2.8 WELCHES ANTIDEPRESSIVUM GEBE CH WEM? . . . . . . . . . . . . . . . 59 3 N E U R O LE P T IK A ...................................................................................... 63 3.1 E IN TE ILU N G ................................................................................................ 64 3.1.1 CHEMSCHE S TRU KTU R................................................................................ 64 3.1.2 NEUROLEPTISCHE POTENZ........................................................................... 65 3.1.3 UNTERSCHIEDLICHE NEBENW IRK .................................................... 65 TYPIKA......................................................................................................... 65 ATYPJKA....................................................................................................... 66 3.2 G E S C H IC H TE ............................................................................................ 67 3.3 A N TIP SYCH OTIKA...................................................................................... 69 3.3.1 W IRKPRINZIPIEN......................................................................................... 69 3 3 .2 REZEPTORBINDUNGSPROFILE....................................................................... 70 3 3 .3 THERAPIE.................................................................................................... 76 PSYCHOSE.................................................................................................... 76 DEL * ......................................................................... . . . . . . . . .. 78 WAHNHAFTE DEPRESSION........................................................................... 78 3 3 .4 EXKURS: DIE CATIE-STUDIE....................................................................... 79 3.3.5 WIRKSTOFFE .............................................................. 81 BENPERIDOL UND HALOPERIDOL.................................................................. 81 RJSPERIDON ................................................................................................ 83 OLANZAPIN.................................................................................................. 85 ARIPIPRAZOL................................................................................................ 88 AM ISULPRID................................................................................................ 91 Q UETIAPIN.................................................................................................. 93 ZIPRASIDON ................................................................................................ 97 SERTINDOL.................................................................................................... 100 CLOZAPIN.................................................................................................... 103 3 3 .6 DEPOTNEUROLEPTIKA................................................................................. 108 3.3.7 WELCHES ANTIPSYCHOTIKUMGEFE 112 3.4 S E D A TIV A .................................................................................................. 116 3.4.1 PROMETHAZIN ............................................................................................. 116 3.4.2 OP*PRAMOL ................................................................................................ 118 3.5 A N TIH Y P E RK IN E TIK A ................................................................................ 120 3.5.1 T IA P RLD ....................................................................................................... 120 3.6 N E B E N -U N D W E C H S E LW IRK U N G E N .................................................... 123 3.6.1 EXTRAPYRAMIDALMOTORISCHE STORUNGEN ( E P M S ) . . . . . . . . . . . . . . . . 123 3.6.2 AKATHISIE .................................................................................................. 124 3 .6 3 METABOLISCHES SYNDROM........................................................................ 125 BAUCHUMFANG ALS LEITKRITERIUM ........................................................... 126 3 6 .4 AGRANULOZYTOSE..................................................................................... 128 3.6.5 QTC-ZEIT-VERLAENGERUNG ........................................................................... 130 4 P H A S E N P R O P H Y LA K TIK A .................................................................... 134 4.1 P HASENPROPHYLAXE.................................................................................. 135 4.2 T H E RA P IE .................................................................................................... 136 4.2.1 MANISCHE EPISODE .................................................................................... 136 4.2.2 DEPRESSIVE EPISODE .................................................................................. 137 4.3 W IR K S T O F F E ............................................................................................... 138 4.3.1 LITHIUM........................................................................................................ 138 4.3.2 VALPROINSAEURE............................................................................................. 143 4.3.3 CARBAMAZEPIN ........................................................................................... 147 4.3.4 LAM OTRIGIN.................................................................................................. 151 5 A N X IO LY T IK A ............................................................................................. 153 5.1 N EUROLEPTANXIOLYSE ............................................................................. 153 5.2 B EN ZO D IAZEP IN E...................................................................................... 154 5.2.1 AQUIVALENZDOSIERUNGEN........................................................................... 155 5.2.2 NEBENWIRKUNGEN...................................................................................... 157 5.2.3 WIRKSTOFFE .................................................................................................. 157 DIAZEPAM .................................................................................................... 157 LORAZEPAM.................................................................................................. 160 6 S C H LA F M IT T E L........................................................................................... 163 6.1 DOXYLAM JN ............................................................................................... 164 6.2 DIE Z*SUBSTANZEN.................................................................................... 165 6.2.1 ZOLPIDEM .................................................................................................... 166 6.2.2 ZOPICLON..................................................................................................... 168 7 A D H S *T H E R A P E U T IK A ........................................................................... 170 7.1 A TOM OXETIN ............................................................................................. 170 7.2 M E TH Y LP H E N ID A T...................................................................................... 172 8 G E N U S S M ITTE L....................................................................................... 178 8.1 A LK O H O L.................................................................................................... 178 8.2 NICOTIN .............................................................................................. 185 8.3 C O FF E IN .................................................................................................... 189 9 ILLE G A LE D R O G E N .................................................................................... 193 9.1 H E RO IN ...................................................................................................... 195 9.2 C O C A IN ...................................................................................................... 208 9.2.1 COCAIN(HYDROCHLORID) ............................................................................. 210 9.2.2 C R A C K ...................................................................................................... 210 9.3 A M P H E TA M IN E ..................................................................................... 212 9.3.1 AMPHETAMIN: SPEED, PEP....................................................................... 216 9.3.2 M D M A ....................................................................................................... 217 9.3.3 METHAMPHETAMIN .................................................................................... 217 9.4 C ANN ABIS.................................................................................................. 219 9.5 G AM M A-H YDROXYBUTTERSAEURE ......................................................... 222 10 G E R O N TO P S Y C H IA TR IE ......................................................................... 224 10.1 WASSER .................................................................................................... 224 10.2 EINDOSIERUNG VON M ED IKAM ENT .................................................. 226 10.3 THERAPIE DES DELIRS M A L T E R ........................................................... 228 10.4 A N TID E M E N TIV A ....................................................................................... 229 10.4.1 * NTEJLUNG.................................................................................................. 229 10.4.2 W * KPRNZPEN....................................................................................* 230 ACETYLCHOLINESTERASEHEMMER................................................................ 230 NMDA_ANTAGONST.................................................................................. 231 10.4.3 THERAPIE.................................................................................................... 231 M OBUS A LZHEIM ER.................................................................................. 231 GEMACHTE DEMENZ.................................................................................. 233 VASKULAERE D EM EN Z.................................................................................. 233 FRONTOTEMPORAL DEMENZ....................................................................... 233 PARKINSON-DEMENZ.................................................................................. 233 LEWY-KORPERCHEN-DEMENZ .................................................................... 234 10.4.4 WIRKSTOFFE ................................................................................................ 234 GALANTAMIN................................................................................................ 234 DONEPEZIL.................................................................................................. 235 RIVASTJGMJN................................................................................................ 236 M EM ANTIN.................................................................................................. 237 10.4.5 NEBENWIRKUNGEN .................................................................................... 238 11 N O T F AE L L E .................................................................................................. 240 111 PHARM AKOTHERAPIE DES ERREGUNGSZUSTANDES . . . . . . . . . . . . . 240 * 2 S U IZ ID A LITAE T.............................................................................................. 245 12 M E D IK A M E N TE N W E C H S E LW IR K U N G E N . . . . . . . . . . . . . . . . . . . 247 G LO SSAR ................................................................................................................ 249 S A C H V E R Z E IC H N IS ............................................................................................. 256
any_adam_object 1
author Dreher, Jan 1971-
author_GND (DE-588)120465655
author_facet Dreher, Jan 1971-
author_role aut
author_sort Dreher, Jan 1971-
author_variant j d jd
building Verbundindex
bvnumber BV043376770
classification_rvk CZ 2000
XI 5803
ctrlnum (OCoLC)956474717
(DE-599)DNB1079863125
dewey-full 610
dewey-hundreds 600 - Technology (Applied sciences)
dewey-ones 610 - Medicine and health
dewey-raw 610
dewey-search 610
dewey-sort 3610
dewey-tens 610 - Medicine and health
discipline Psychologie
Medizin
edition 2., vollständig aktualisierte und erweiterte Auflage
format Book
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02643nam a2200553 c 4500</leader><controlfield tag="001">BV043376770</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20160915 </controlfield><controlfield tag="007">t|</controlfield><controlfield tag="008">160218s2016 xx a||| |||| 00||| ger d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">15,N51</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1079863125</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3794531833</subfield><subfield code="9">3-7945-3183-3</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783794531837</subfield><subfield code="c">: ca. EUR 25.70 (AT), ca. EUR 24.99 (DE)</subfield><subfield code="9">978-3-7945-3183-7</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9783794531837</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)956474717</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1079863125</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">ger</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-1052</subfield><subfield code="a">DE-70</subfield><subfield code="a">DE-11</subfield><subfield code="a">DE-M483</subfield><subfield code="a">DE-824</subfield><subfield code="a">DE-1949</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-128</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">CZ 2000</subfield><subfield code="0">(DE-625)19239:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 5803</subfield><subfield code="0">(DE-625)153018:12909</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">QV 77</subfield><subfield code="2">nlm</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Dreher, Jan</subfield><subfield code="d">1971-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)120465655</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Psychopharmakotherapie griffbereit</subfield><subfield code="b">Medikamente, psychoaktive Genussmittel und Drogen</subfield><subfield code="c">Jan Dreher</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">2., vollständig aktualisierte und erweiterte Auflage</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Stuttgart</subfield><subfield code="b">Schattauer</subfield><subfield code="c">[2016]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">© 2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XIV, 267 Seiten</subfield><subfield code="b">10 Illustrationen, Diagramme</subfield><subfield code="c">18.5 cm x 12 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">griffbereit</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Mental Disorders - drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Psychotropic Drugs - therapeutic use</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Psychopharmakotherapie</subfield><subfield code="0">(DE-588)4236424-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Ärzte in Weiterbildung zum Facharzt für Psychiatrie und Psychotherapie; Haus- und Allgemeinärzte; andere Ärzte, die immer wieder mal mit Psychopharmakologie zu tun haben; Medizinstudenten; Psychologen in Ausbildung (speziell Psychologen in Weiterbildung zum Psychologischen Psychotherapeuten); Pflegekräfte auf psychiatrischen Stationen; Sozialarbeiter, die in einer psychiatrischen Klinik tätig sind; Betroffene und Angehörige</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ADHS-Therapeutika</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Acetylcholinesterasehemmer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">extrapyramidalmotorische Störungen</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Psychopharmakotherapie</subfield><subfield code="0">(DE-588)4236424-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Schattauer GmbH</subfield><subfield code="0">(DE-588)1065173687</subfield><subfield code="4">pbl</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe, EPUB</subfield><subfield code="z">978-3-7945-9041-4</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe, PDF</subfield><subfield code="z">978-3-7945-9011-7</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&amp;doc_library=BVB01&amp;local_base=BVB01&amp;doc_number=028795572&amp;sequence=000001&amp;line_number=0001&amp;func_code=DB_RECORDS&amp;service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028795572</subfield></datafield></record></collection>
id DE-604.BV043376770
illustrated Illustrated
indexdate 2025-02-03T17:41:49Z
institution BVB
institution_GND (DE-588)1065173687
isbn 3794531833
9783794531837
language German
oai_aleph_id oai:aleph.bib-bvb.de:BVB01-028795572
oclc_num 956474717
open_access_boolean
owner DE-355
DE-BY-UBR
DE-1052
DE-70
DE-11
DE-M483
DE-824
DE-1949
DE-19
DE-BY-UBM
DE-128
owner_facet DE-355
DE-BY-UBR
DE-1052
DE-70
DE-11
DE-M483
DE-824
DE-1949
DE-19
DE-BY-UBM
DE-128
physical XIV, 267 Seiten 10 Illustrationen, Diagramme 18.5 cm x 12 cm
publishDate 2016
publishDateSearch 2016
publishDateSort 2016
publisher Schattauer
record_format marc
series2 griffbereit
spellingShingle Dreher, Jan 1971-
Psychopharmakotherapie griffbereit Medikamente, psychoaktive Genussmittel und Drogen
Mental Disorders - drug therapy
Psychotropic Drugs - therapeutic use
Psychopharmakotherapie (DE-588)4236424-3 gnd
subject_GND (DE-588)4236424-3
title Psychopharmakotherapie griffbereit Medikamente, psychoaktive Genussmittel und Drogen
title_auth Psychopharmakotherapie griffbereit Medikamente, psychoaktive Genussmittel und Drogen
title_exact_search Psychopharmakotherapie griffbereit Medikamente, psychoaktive Genussmittel und Drogen
title_full Psychopharmakotherapie griffbereit Medikamente, psychoaktive Genussmittel und Drogen Jan Dreher
title_fullStr Psychopharmakotherapie griffbereit Medikamente, psychoaktive Genussmittel und Drogen Jan Dreher
title_full_unstemmed Psychopharmakotherapie griffbereit Medikamente, psychoaktive Genussmittel und Drogen Jan Dreher
title_short Psychopharmakotherapie griffbereit
title_sort psychopharmakotherapie griffbereit medikamente psychoaktive genussmittel und drogen
title_sub Medikamente, psychoaktive Genussmittel und Drogen
topic Mental Disorders - drug therapy
Psychotropic Drugs - therapeutic use
Psychopharmakotherapie (DE-588)4236424-3 gnd
topic_facet Mental Disorders - drug therapy
Psychotropic Drugs - therapeutic use
Psychopharmakotherapie
url http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=028795572&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA
work_keys_str_mv AT dreherjan psychopharmakotherapiegriffbereitmedikamentepsychoaktivegenussmittelunddrogen
AT schattauergmbh psychopharmakotherapiegriffbereitmedikamentepsychoaktivegenussmittelunddrogen